Comparator: efavirenz

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Acquired Immunodeficiency SyndromeHIV Infections

Phase 2

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

CompletedNCT00100048

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2005-01-31End: 2010-07-31Updated: 2015-09-09

Phase 3

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

CompletedNCT00369941

Merck Sharp & Dohme LLCHIV Infections

Start: 2006-08-31End: 2012-02-29Updated: 2017-03-21

Related Papers

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

2011-10-01135 citations

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

2009-08-03459 citations

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

2007-10-01297 citations